Weekly Digest – May 2025 Weekly Digest – May 2025 09 May 2025: RemeGen’s Disitamab vedotin gains approval in China for its third indication making it the first ADC approved for HER2-positive advanced Breast cancer with liver metastasis globally China’s […]
Weekly Digest – May 2025 Weekly Digest – May 2025 14 May 2025: U.S. FDA Approves EMRELIS (Telisotuzumab vedotin) for adults with previously treated advanced Non-Small Cell Lung Cancer (NSCLC) with high c-Met protein overexpression The FDA granted accelerated approval […]
Weekly Digest – May 2025 Weekly Digest – May 2025 14 May 2025: ADC Therapeutics announces presentation of LOTIS-7 clinical trial data at the European Hematology Association 2025 congress (EHA2025) and the 18th international conference on malignant lymphoma (ICML) LOTIS-7 […]
Weekly Digest – May 2025 Weekly Digest – May 2025 09 May 2025: Minghui Pharmaceutical announces strategic partnership and licensing agreement with Qilu Pharmaceutical to develop B7-H3 ADC in greater china Minghui Pharmaceutical has entered an exclusive licensing and collaboration […]
Weekly Digest – May 2025 Weekly Digest – May 2025 15 May 2025: SparX Biopharmaceutical announces research agreement with Mitsubishi Tanabe Pharma America to advance novel antibody-drug conjugates SparX Biopharmaceutical has entered a research agreement with Mitsubishi Tanabe Pharma America […]
Weekly Digest – May 2025 Weekly Digest – May 2025 13 May 2025: LigaChem Biosciences partners with Y Biologics for antibody technology LigaChem has secured exclusive global rights to develop antibody-drug conjugates (ADCs) using a novel antibody from Y Biologics, […]
